Anne Moon

Geisinger Medical Center — United States

Biochemistry, Genetics and Molecular Biology · Life Sciences

52h-index9.3kcitations141works1.02yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Congenital heart defects research(49), Virus-based gene therapy research(32), Cancer Research and Treatments(23), Viral Infectious Diseases and Gene Expression in Insects(22), Congenital Heart Disease Studies(15)

Publications140 total

Discovery and characterization of anti-cancer peptides from a random peptide library
PLoS ONE·2024· 1 citedOpen Access
1338 Crystallography-guided characterization of novel cytosolic DNase 3’ repair exonuclease 1 (TREX1) inhibitors
Regular and Young Investigator Award Abstracts·2023Open Access
Loss of<i>Tbx3</i>in Mouse Eye Causes Retinal Angiogenesis Defects Reminiscent of Human Disease
Investigative Ophthalmology & Visual Science·2023· 2 citedOpen Access
Aberrant differentiation of second heart field mesoderm prefigures cellular defects in the outflow tract in response to loss of FGF8
Developmental Biology·2023· 6 citedOpen Access
Abstract 1636: Generation of novel potent human TREX1 inhibitors facilitated by crystallography
Cancer Research·2023· 2 cited
Supplementary Methods from Oncolytic Vaccinia Virus Disrupts Tumor-Associated Vasculature in Humans
2023Open Access
Supplementary Figure 3 from Oncolytic Vaccinia Virus Disrupts Tumor-Associated Vasculature in Humans
2023Open Access
Supplementary Figure 2 from Oncolytic Vaccinia Virus Disrupts Tumor-Associated Vasculature in Humans
2023Open Access
Data from Oncolytic Vaccinia Virus Disrupts Tumor-Associated Vasculature in Humans
2023Open Access
Supplementary Figure 2 from Oncolytic Vaccinia Virus Disrupts Tumor-Associated Vasculature in Humans
2023Open Access
Supplementary Table 1 from Oncolytic Vaccinia Virus Disrupts Tumor-Associated Vasculature in Humans
2023Open Access
Supplementary Figure 4 from Oncolytic Vaccinia Virus Disrupts Tumor-Associated Vasculature in Humans
2023Open Access
Supplementary Video 2 from Oncolytic Vaccinia Virus Disrupts Tumor-Associated Vasculature in Humans
2023Open Access
Data from Oncolytic Vaccinia Virus Disrupts Tumor-Associated Vasculature in Humans
2023Open Access
Supplementary Figure 3 from Oncolytic Vaccinia Virus Disrupts Tumor-Associated Vasculature in Humans
2023Open Access
Supplementary Figure 1 from Oncolytic Vaccinia Virus Disrupts Tumor-Associated Vasculature in Humans
2023Open Access
Supplementary Figure 4 from Oncolytic Vaccinia Virus Disrupts Tumor-Associated Vasculature in Humans
2023Open Access
Supplementary Video 1 from Oncolytic Vaccinia Virus Disrupts Tumor-Associated Vasculature in Humans
2023Open Access
Supplementary Figure 1 from Oncolytic Vaccinia Virus Disrupts Tumor-Associated Vasculature in Humans
2023Open Access
Supplementary Table 1 from Oncolytic Vaccinia Virus Disrupts Tumor-Associated Vasculature in Humans
2023Open Access
page 1 of 7Next →

Frequent Co-authors

Caroline J. Breitbach(11), David H. Kirn(11), John C. Bell(9), James M. Burke(7), Tae-Ho Hwang(7), Manijeh Daneshmand(6), Mario R. Capecchi(5), Jeong Heo(4), Tae-Ho Hwang(4), Deborah U. Frank(4), James F. Martin(4), Mong Cho(3), Richard H. Patt(3), Adina Pelusio(3), Naomi De Silva(3), Kelley A. Parato(3), Chen‐Leng Cai(3), Eon Joo Park(3), Pavan Kumar P(3), Shinichi Miyagawa(3)